Fused Or Hybrid Cell, Per Se Patents (Class 435/346)
-
Publication number: 20100323455Abstract: The present invention includes a diagnostic assay for the detection and determination of MGP in a human serum sample, which comprises the use of one or more antibodies, preferably monoclonal antibodies, specifically recognizing epitopes on and/or conformations of human Matrix Gla-Protein. A method is provided for using MGP-related antigens as biomarkers for certain diseases, for example, atherosclerosis and other vascular diseases, and angiogenesis/neogenesis in tumor development. Monoclonal antibodies of class IgG are described for use in the assay, which are defined herein as mAb3-15, mAb35-49[Glu], mAb35-49[Gla], mAb35-53[Glu], and mAb35-53[Gla]. Polyclonal antibodies and methods are also disclosed for measuring MGP in a human serum sample.Type: ApplicationFiled: April 20, 2010Publication date: December 23, 2010Applicant: MGP DIAGNOSTICS ASInventor: CEES VERMEER
-
Publication number: 20100316634Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.Type: ApplicationFiled: March 1, 2010Publication date: December 16, 2010Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
-
Publication number: 20100317546Abstract: The present invention relates, in one aspect, to a vector comprising (a) a first polynucleotide capable of encoding a first (poly)peptide comprising at least one cysteine residue, and (b) a second polynucleotide capable of encoding a second (poly)peptide which is a cell surface anchor comprising at least one cysteine residue, wherein the vector is operable in a eukaryotic host cell to express and to cause or allow the attachment of said first (poly)peptide to said second (poly)peptide by formation of a disulfide bond between said cysteine residues comprised within said first (polypeptide and said second (poly)peptide, respectively, wherein said first (poly)peptide is exhibited at the surface of a eukaryotic host cell.Type: ApplicationFiled: January 9, 2009Publication date: December 16, 2010Applicant: MORPHOSYS AGInventors: Markus Enzelberger, Philippe Thiel, Solveig Peters, Rüdiger Neun, Stephen Yoder
-
Publication number: 20100311170Abstract: The present invention discloses a method for reprogramming a differentiated cell to an undifferentiated stem cell comprising fusing a pluripotent cell with a differentiated cell to form a fused cell, wherein the pluripotent cell is pre-treated or the fused cell is treated with a suitable amount of a Wnt/?-catenin pathway activator.Type: ApplicationFiled: February 10, 2009Publication date: December 9, 2010Inventors: Maria Pia Cosma, Frederic Lluis Viñas
-
Patent number: 7838247Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.Type: GrantFiled: August 20, 2007Date of Patent: November 23, 2010Assignees: HSC Research and Development Limited Partnership, The Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Patent number: 7829083Abstract: A novel gene apparently encoding a transmembrane glycoprotein has been successfully isolated by constructing a cDNA library of 4 kb or above in size from mRNA expressed in human adult brain and analyzing the structures of the cDNAs contained within said library by the shotgun method. The novel gene shows brain-specific expression and the protein encoded by said gene has a typical PDZ binding motif.Type: GrantFiled: January 11, 2008Date of Patent: November 9, 2010Assignees: Chugai Seiyaku Kabushiki Kaisha, Kazusa DNA Research InstituteInventors: Takahiro Nagase, Shoji Miyata, Nobuo Nomura, Osamu Ohara, Shin-ichi Funahashi
-
Publication number: 20100278873Abstract: The invention is concerned with fusions of dendritic cells and with tumor or cancer cells. Also provided are methods of making and using these cell fusions, including methods of adoptive immunotherapy as well as methods of stimulating anti-tumor immunity using fused cells and anti-CD3/CD28 antibodies.Type: ApplicationFiled: November 7, 2008Publication date: November 4, 2010Inventors: David Avigan, Donald Kufe
-
Publication number: 20100279316Abstract: The present invention relates to antibodies that bind phosphorylated forms of IRAK4, methods of using such antibodies to detect IRAK4 biological activity, and methods for the detection, diagnosis, and prognostication of pathological conditions related to IRAK4 biological activity. ERAK4 is one member of a small family of highly conserved cytoplasmic signal transduction proteins characterized by the presence of an N-terminal “death domain” and a C-terminal serine-threonine kinase domain. IRAK4 functions in cytoplasmic signal transduction pathways by interacting with membrane spanning proteins which play, inter alia, critical roles in vertebrate immune system function.Type: ApplicationFiled: January 9, 2008Publication date: November 4, 2010Inventors: Leonid Gorelik, Darren P. Baker, Catherine A. Hession, Karyn Van De Mark, Robert M. Arduini, Craig Wildes
-
Publication number: 20100279401Abstract: The present invention provides T cell hybridomas and related compositions and assay systems for investigative, diagnostic, and therapeutic use in modulating T cell receptor (TCR)-mediated immune response. The T cell hybridomas of the invention are typically constructed by fusing a naïve or early central memory T cell isolated from a mammalian subject with an immortalizing fusion partner (e.g. mammalian lymphoid tumor cell) to yield clonal T cell hybrids. The resulting T cell hybridomas exhibit antigen (Ag)-specific proliferation responsiveness over a background level of proliferation of the hybridomas. These hybridomas are useful for screening, identifying, and characterizing T cell immune modulatory agents, for example recombinant T cell receptor ligands (RTLs) and other agents that can modulate TCR-mediated T cell immune responses.Type: ApplicationFiled: July 7, 2005Publication date: November 4, 2010Inventors: Gregory G. Burrows, Yuan K. Chou, Arthur A. Vandenbark
-
Patent number: 7820797Abstract: A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.Type: GrantFiled: July 3, 2008Date of Patent: October 26, 2010Assignee: University of Georgia Research Foundation, Inc.Inventor: Geert-Jan Boons
-
Publication number: 20100266606Abstract: The present invention relates to a monoclonal antibody against hemagglutinin of highly pathogenic avian influenza virus subtype H5 or functional fragment thereof, a hybridoma producing the monoclonal antibody, and a composition comprising the monoclonal antibody or functional fragment thereof. In addition, the present invention relates to a method for preventing or treating influenza virus infection by administering the composition to a subject, and an assay kit for influenza virus comprising the monoclonal antibody or functional fragment thereof.Type: ApplicationFiled: April 26, 2010Publication date: October 21, 2010Applicants: STANDARD DIAGNOSTICS, INC., BIONOTE, INC.Inventors: Young Shik Cho, Gun Woo Ha, Jin Sik Oh, Byung Gi Cho, Yun Jung Lee
-
Publication number: 20100266493Abstract: The invention provides antibodies that bind the thyroid stimulating hormone receptor (TSHR), especially in humans, and their uses in diagnostic and therapeutic roles. The invention also provides hybridomas for producing such antibodies.Type: ApplicationFiled: March 29, 2007Publication date: October 21, 2010Applicant: KING'S COLLEGE LONDONInventors: Jasvinder-Paul Singh Banga, Jacqueline Ann Gilbert, Deborah Dunn-Walters
-
Publication number: 20100255515Abstract: The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index.Type: ApplicationFiled: June 17, 2010Publication date: October 7, 2010Applicant: Genentech, Inc.Inventors: Yu-Ju G. Meng, Kyu H. Hong, Johnny Gutierrez
-
Publication number: 20100248211Abstract: An object of the present invention is to enable to accurately quantify HBs antigen in the samples for which measured values are low or false-negative results by the conventional assaying method of HBs antigen. In the method of assaying HBs antigen according to the present invention, at least one inner capture probe that binds to a first inner region peptide consisting of 26th to 80th amino acid residues of HBs antigen and at least one outer capture probe that binds to a second outer region peptide consisting of 98th to 156th amino acid residues of HBs antigen are used as capture probes; and at least one inner detection probe which binds to the first inner region and at least one outer detection probe which binds to the second outer region are used as detection probes.Type: ApplicationFiled: October 30, 2007Publication date: September 30, 2010Inventors: Naoko Matsubara, Yasuhiro Sugamata, Osamu Kusano, Noriko Shirata
-
Publication number: 20100248262Abstract: A method for measuring a fibronectin fragment which is easy to handle and has excellent measuring accuracy, specificity and reproducibility is provided. An anti-fibronectin fragment monoclonal antibody which reacts with a human fibronectin fragment but does not react with human fibronectin, a measuring reagent containing the monoclonal antibody, a method for measuring a fibronectin fragment which uses the monoclonal antibody and a hybridoma which produces the monoclonal antibody are provided.Type: ApplicationFiled: March 31, 2010Publication date: September 30, 2010Applicant: TAKARA BIO INC.Inventors: Chika KATO, Yuka SANO, Kyoko KAMIHAGI, Ikunoshin KATO
-
Publication number: 20100247502Abstract: The present invention is directed to methods and compositions for slowing or inhibiting the growth of tumors and decreasing the size of existing tumors. The compositions include dendritic cells contacted with tumor/B-cell hybrid cells and various T-cells contacted with tumor/B-cell hybrid cells (TBH cells). The present invention further encompasses methods of generating such compositions and methods of use of such compositions.Type: ApplicationFiled: January 6, 2010Publication date: September 30, 2010Inventor: Gustavo Antonio MOVIGLIA
-
Publication number: 20100248274Abstract: Disclosed is a novel high-sensitive ProGRP measurement method, which is free from problems such as the fluctuations in measurement values and the operational constraints (e.g., the constraints on the handling of a sample). Specifically disclosed is a method for the measurement of a gastrin-releasing peptide precursor and/or a digested product thereof using at least two different antibodies each of which can recognize an epitope represented by the amino acid sequence consisting of amino acid 47 to amino acid 68 of the amino acid sequence set forth in SEQ ID NO:1. The method can detect a ProGRP or a digested product thereof in a refrigerated sample within a shorter period, by using the sample in a smaller amount, and with a higher degree of detective sensitivity, compared with the conventional methods.Type: ApplicationFiled: September 29, 2008Publication date: September 30, 2010Applicant: Advanced Life Science Institute Inc.Inventors: Katsumi Aoyagi, Yukiji Izawa
-
Patent number: 7799562Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: GrantFiled: October 26, 2009Date of Patent: September 21, 2010Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Malik Merza
-
Publication number: 20100227395Abstract: The present invention provides a dendritic cell-based vaccine by fusing a canine tumor cell and an allogeneic dendritic cell, and a method for preparing the same. The fusion cells expressing canine tumor antigens are generated by fusing canine bone marrow-derived dendritic cells and canine tumor cells. The canine immune system can be induced to produce tumor specific T lymphocytes and natural killer cells when the fusion cells used as a vaccine is injected into a canine body.Type: ApplicationFiled: June 12, 2009Publication date: September 9, 2010Applicant: NATIONAL TAIWAN UNIVERSITYInventors: Rea-Min Chu, Chien-Chun Pai, Tien-Fu Chuang
-
Publication number: 20100227335Abstract: Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MMP-7. Monoclonal antibodies having the binding characteristics of an MMP-7 antibody of the invention and monoclonal antibodies that bind to an MMP-7 epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce an MMP-7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed MMP-7 monoclonal antibodies and for practicing the methods of the invention are further provided.Type: ApplicationFiled: March 5, 2010Publication date: September 9, 2010Applicant: Becton, Dickinson and CompanyInventors: Jeffrey P. Baker, Robert L. Cheek, Eric P. Dixon, Timothy J. Fischer, Steven L. Knapp, Stephen G. Simkins, Clark M. Whitehead
-
Publication number: 20100227343Abstract: Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to glycodelin. Monoclonal antibodies having the binding characteristics of a glycodelin antibody of the invention and monoclonal antibodies that bind to a glycodelin epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce a glycodelin monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed glycodelin monoclonal antibodies and for practicing the methods of the invention are further provided.Type: ApplicationFiled: March 5, 2010Publication date: September 9, 2010Applicant: Becton, Dickinson and CompanyInventors: Robert L. Cheek, Eric P. Dixon, Timothy J. Fischer, John W. Groelke, Steven L. Knapp, Stephen G. Simkins, Clark M. Whitehead
-
Publication number: 20100209428Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.Type: ApplicationFiled: October 8, 2008Publication date: August 19, 2010Inventors: Yoshiharu Hiruma, Eisuke Tsuda
-
Publication number: 20100212037Abstract: The present invention relates to the human and murine melanoma inhibitory activity protein-2 (MIA-2) and to the nucleic acids encoding said proteins including a method for producing such proteins by recombinant techniques. The invention also relates to methods for utilizing such proteins for tissue regeneration, tumor treatment including to control the proliferation and differentiation of liver cells in vivo and in vitro. The invention further relates to diagnostic assays including the human and murine antibodies or aptamers and their use in therapy and diagnosis. Further it relates to diagnostic assays applying specific primers for the diagnostic of liver disease.Type: ApplicationFiled: December 9, 2009Publication date: August 19, 2010Inventors: Anja Katrin Bosserhoff, Claus Hellerbrand, de Buettner
-
Publication number: 20100209905Abstract: A novel surface exposed protein of Haemophilus influenzae or related Haemophilus species is described. The protein named protein D is an Ig receptor for human IgD and has an apparent molecular weight of 42,000. Protein D can be detected in all of 116 encapsulated and non-encapsulated isolates of H. influenzae studied. The protein from all strains shows in addition to the same apparent molecular weight immunogenic similarities since protein D from all strains interacts with three different mouse monoclonal antibodies and monoclonal human IgD. A method for purification of protein D is described. Cloning of the protein D gene from H. influenzae in E. coli is described as well as the nucleotide sequence and the deduced amino acid sequence.Type: ApplicationFiled: January 29, 2010Publication date: August 19, 2010Inventor: Arne FORSGREN
-
Publication number: 20100209417Abstract: Provided is an antibody that selectively binds to an epitope formed by residues 1-11 of A? in an A? oligomer, a method comprising using the antibody to treat a disease characterized by such an A? amyloid deposit in a patient, and kits comprising same.Type: ApplicationFiled: November 21, 2006Publication date: August 19, 2010Inventors: Virginia M.Y. Lee, Edward B. Lee, John Q. Trojanowski
-
Patent number: 7776560Abstract: The present invention relates to a novel member of the tumor necrosis factor family of receptors. In particular, isolated nucleic acid molecules are provided encoding the human TR9 receptor. TR9 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR9 receptor activity.Type: GrantFiled: July 20, 2007Date of Patent: August 17, 2010Assignee: Human Genome Scienes, Inc.Inventors: Jian Ni, Guo-Liang Yu, Ping Fan, Reiner L. Gentz
-
Publication number: 20100204453Abstract: A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.Type: ApplicationFiled: January 26, 2010Publication date: August 12, 2010Inventors: Arthur B. RAITANO, Karen Jane Meyrick Morrison, Wangmao Ge, Pia M. Challita-Eid, Aya Jakobovits
-
Publication number: 20100196384Abstract: The present invention discloses anti-histone H1 monoclonal antibodies, hybridomas for the production thereof, and polypeptides, which are useful for suppressing, predicting, or diagnosing transplant rejection in organ transplantation.Type: ApplicationFiled: April 19, 2010Publication date: August 5, 2010Inventors: Takeshi Goto, Shuji Sato, Kazuhisa Ono, Seiko Shigeta, Seiji Kawamoto, Shigeru Goto
-
Publication number: 20100196386Abstract: The present invention relates to ligands of HVEM for the treatment of hematologic malignancies, in particular Chronic lymphocytic leukaemia, and for the treatment of autoimmune diseases.Type: ApplicationFiled: June 2, 2008Publication date: August 5, 2010Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LA MEDITERRANEEInventors: Daniel Olive, Alemseged Truneh, Christine Pasero
-
Publication number: 20100197009Abstract: The application relates to antibodies which recognize the AviTag™ peptide of sequence MSGLNDIFEAQKIEWHE (SEQ ID No. 1) and to fragments thereof which recognize SEQ ID No. 1, wherein said antibodies or said fragments thereof recognize polypeptides containing SEQ ID No. 1 at their NH2 terminus and polypeptides containing SEQ ID No. 1 at their COOH terminus. The application further relates to a method for sorting target cells presenting on their surface a surface marker from a mixed cell population comprising the steps of: a) incubating said mixed cell population with a tagged adapter which binds to said surface marker of said target cells, wherein said adapter is bound to an antibody which recognizes said tag, and wherein said antibody is immobilized on a solid support. b) collecting said target cells.Type: ApplicationFiled: July 11, 2008Publication date: August 5, 2010Applicant: INSERM(Institut National de la Sante et de la Recherche Medicale)Inventors: Francois Lang, Karine Bernardeau, Regis Bouquie, Nathalie Labarriere
-
Publication number: 20100196392Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.Type: ApplicationFiled: July 17, 2009Publication date: August 5, 2010Applicant: Kyowa Hakko Kirin Co., Ltd.Inventors: Norihiko SHIRAISHI, Akiko Furuya, Hiroe Toki, Hiroshi Ando, Masayo Suzuki, Tsuguo Kubota
-
Publication number: 20100190185Abstract: A monoclonal antibody or fragment thereof, capable of specifically binding to at least one epitope of sH2a and/or being elicited by at least one epitope, and assays, kits, and methods of use thereof diagnosing liver disease or condition, detecting liver function and assessing the efficacy of therapy to a liver disease.Type: ApplicationFiled: April 13, 2010Publication date: July 29, 2010Applicant: Ramot At Tel Aviv University Ltd.Inventors: Gerardo Zelmar LEDERKREMER, Maria Kondratyev
-
Publication number: 20100183618Abstract: Problem to Be Solved It is intended to provide an antibody having an inhibitory activity against cell malignant transformation and/or tumor cell growth, etc. Solution The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.Type: ApplicationFiled: February 25, 2010Publication date: July 22, 2010Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Jun Hasegawa, Toshiaki Ohtsuka, Atsushi Urano, Junko Yamaguchi, Toshinori Agatsuma, Kaori Nakahara, Takeshi Takizawa
-
Publication number: 20100167377Abstract: Recombinant viruses, isolated nucleic acids and methods of generating same encoding for a Rhabdoviral G stem polypeptide are disclosed. Methods, compounds and compositions for target cell fusion potentiation mediated by Rhabdoviral G stem polypeptides, and applications of same are provided.Type: ApplicationFiled: December 23, 2002Publication date: July 1, 2010Inventors: Michael A. Whitt, Clinton S. Robison
-
Publication number: 20100162419Abstract: Provided herein are an isolated or enriched population of tumor initiating cells derived from normal cells, cells susceptible to neoplasia, or neoplastic cells. Methods of use of the cells for screening for anti-hyperproliferative agents, and use of the cells for animal models of hyperproliferative disorders including metastatic cancer, diagnostic methods, and therapeutic methods are provided.Type: ApplicationFiled: June 30, 2009Publication date: June 24, 2010Applicant: Caritas St. Elizabeth Medical Center of Boston, Inc.Inventor: Lynn Hlatky
-
Publication number: 20100158900Abstract: Described herein are deposited hybridoma cell lines and the monoclonal antibodies produced by these hybridomas, and antigen binding fragments thereof. These monoclonal antibodies and antigen binding fragments specifically bind marinobufagenin. The disclosure also encompasses the use of these monoclonal antibodies or antigen binding fragments in a method for detecting the presence of marinobufagenin in a biological sample. Also provided are methods for the use of these monoclonal antibodies or antigen binding fragments as prophylactic, therapeutic, and diagnostic agents for the detection, inhibition and treatment of a cardiovascular disease, for example, essential hypertension, hypertension associated with preeclampsia, eclampsia, or renal failure, or myocardial fibrosis in a subject.Type: ApplicationFiled: June 26, 2006Publication date: June 24, 2010Inventors: Alexei Bagrov, Olga V. Fedorova, Edward G. Lakatta, Andrey Simbirtsev, Alexander Kotov, Nikolai Kolodkin
-
Publication number: 20100150902Abstract: The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.Type: ApplicationFiled: October 9, 2009Publication date: June 17, 2010Inventor: Jean-Francois HAEUW
-
Publication number: 20100151495Abstract: The invention discloses nearly 443 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Protein kinases (including Serine/Threonine dual specificity, and Tyrosine kinases), Adaptor/Scaffold proteins, Transcription factors, Phospoatases, Tumor supressors, Ubiquitin conjugating system proteins, Translation initiation complex proteins, RNA binding proteins, Apoptosis proteins, Adhesion proteins, G protein regulators/GTPase activating protein/Guanine nucleotide exchange factor proteins, and DNA binding/replication/repair proteins, as well as other protein types.Type: ApplicationFiled: February 29, 2008Publication date: June 17, 2010Inventors: Roberto Polakiewicz, Ailan Guo, Albrecht Moritz, Klarisa Rikova, Kimberly Lee, Erik Spek, Yu Li, Charles Farnsworth
-
Publication number: 20100146650Abstract: The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer.Type: ApplicationFiled: September 27, 2007Publication date: June 10, 2010Applicant: Pierre Fabre MedicamentInventors: Liliane Goetsch, Alexandra Jouhanneaud
-
Patent number: 7731969Abstract: Disclosed are methods for producing immortalized antigen-specific plasma cells and antibodies which include depleting an immunized cell population of CD138-positive cells and activating the depleted cells. The methods may be used to improve the efficiency of obtaining immortalized antigen-specific plasma cells.Type: GrantFiled: December 6, 2007Date of Patent: June 8, 2010Assignee: NeoClone Biotechnology International, LLCInventors: Ward C. Tucker, Mark W. Jackson, Rachel H. Kravitz
-
Patent number: 7731966Abstract: Monoclonal antibodies prepared against platelet ?3 integrin useful in antithrombotic therapy or in models of thrombosis, thrombocytopenia, and anti-angiogenesis. The antibodies are prepared using ?3 integrin deficient (?3?/?) mice immunized against platelets or ?3 integrin fragments.Type: GrantFiled: April 11, 2008Date of Patent: June 8, 2010Assignee: Canadian Blood ServicesInventors: Heyu Ni, Guangheng Zhu
-
Publication number: 20100129346Abstract: The present invention relates to improved antibodies which bind to C5aR and which are useful in diagnosis and therapeutic methods.Type: ApplicationFiled: August 22, 2007Publication date: May 27, 2010Applicant: G2 INFLAMMATION PTY LTD.Inventor: Charles Reay Mackay
-
Patent number: 7718779Abstract: In this application are described monoclonal antibodies which specifically recognize V antigen of Y. pestis and epitopes recognized by these monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of plague infections in vitro and in vivo.Type: GrantFiled: November 12, 2004Date of Patent: May 18, 2010Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Tran C. Chanh, Gerard P. Andrews, Jeffrey J. Adamovicz, Bradford S. Powell
-
Publication number: 20100111868Abstract: Isolated monoclonal antibodies that bind and/or neutralize anthrax protective antigen (PA) are disclosed as well as hybridomas secreting such antibodies. The invention also provides anti-PA fragments of the antibodies of the invention and recombinantly produced antibodies. Also provided are pharmaceutical compositions containing the antibodies or antibody fragments and uses and methods involving same.Type: ApplicationFiled: September 3, 2009Publication date: May 6, 2010Inventor: Wei-Gang HU
-
Publication number: 20100111964Abstract: This invention relates to the discovery that pleiotrophin binds to and activates a pleiotrophin-receptor which is responsible for the events associated with pleiotrophin activity including tumorigenesis, cell proliferation, and cell invasion. By interfering with that association, the cascade of events associated with pleiotrophin activity can be prevented or reversed. Further, by evaluating the effect of different compounds and conditions on the interaction, new drugs and treatments can be identified for use in preventing certain cancers and growth and developmental disorders.Type: ApplicationFiled: September 11, 2009Publication date: May 6, 2010Applicant: GEORGETOWN UNIVERSITYInventor: Anton Wellstein
-
Publication number: 20100104530Abstract: Monoclonal antibodies, in particular monoclonal antibodies to the VPAC1 receptor protein, compositions containing them and nucleic acid sequences encoding them. Host cells expressing said monoclonal antibodies, recombinant (expression) vectors and methods for producing said antibodies. Prevention or treatment of thrombocytopenia with antibodies to the VPAC1 receptor.Type: ApplicationFiled: June 26, 2008Publication date: April 29, 2010Inventors: Kathleen Freson, Chris Van Geet, Marc Hoylaerts, Jean-Marie Stassen
-
Publication number: 20100100979Abstract: It is an object of the present invention to provide diagnostic reagents, pharmaceuticals and the like for particular diseases, and providing means that are useful in developing such reagents, pharmaceuticals and the like. The present invention provides a novel polypeptide and a specific partial peptide thereof, as well as a novel polynucleotide and a specific partial nucleotide thereof, that can be used as cancer-specific biomarkers; an expression vector for such a polynucleotide and a specific partial peptide thereof; a transformant incorporating such an expression vector; an antisense molecule, RNAi-inducing nucleic acid (e.g., siRNA), aptamer, or antibody for a cancer-specific biomarker, and a composition comprising the same; a mammalian cell or non-human mammal wherein the expression or a function of a cancer-specific biomarker is regulated; a measuring means (e.g., primer set, nucleic acid probe, antibody, aptamer) for a cancer-specific biomarker, and a reagent comprising them and the like.Type: ApplicationFiled: March 13, 2008Publication date: April 22, 2010Applicant: REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD.Inventors: Ai Wakamatsu, Junichi Yamamoto, Takao Isogai
-
Publication number: 20100098695Abstract: The invention provides a polypeptide and a specific partial peptide thereof, as well as a polynucleotide and a specific partial nucleotide thereof, that can be used as a biomarker specific for the brain/nerves or specific for nerve differentiation; an expression vector for such a polynucleotide and a specific partial peptide thereof; a transformant incorporating such an expression vector; an antisense molecule, RNAi-inducing nucleic acid (e.g., siRNA), aptamer, or antibody for such a biomarker, and a composition comprising the same; a mammalian cell or non-human mammal wherein the expression or a function of such a biomarker is regulated; a measuring means (e.g., primer set, nucleic acid probe, antibody, aptamer) for such a biomarker, and a reagent comprising the same and the like.Type: ApplicationFiled: March 13, 2008Publication date: April 22, 2010Applicant: REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD.Inventors: Ai Wakamatsu, Junichi Yamamoto, Takao Isogai
-
Publication number: 20100093080Abstract: Disclosed is a novel method for formation of a tooth by producing a chimera embryoid body using an undifferentiated cell and a dental mesenchymal cell derived from a mammal of the same species as that of the target mammal and then cultivating the chimera embryoid body on a three-dimensional matrix. A tooth is formed by co-cultivating an undifferentiated cell and a dental mesenchymal cell derived from a mammal of the same species as that of the target mammal in the presence of an induction factor to produce a chimera embryoid body, and then cultivating the chimera embryoid body on a three-dimensional matrix.Type: ApplicationFiled: July 25, 2006Publication date: April 15, 2010Applicant: Matsumoto Dental UniversityInventors: Mariko Yamaki, Hidehiro Ozawa, Satoshi Ebina
-
Publication number: 20100093008Abstract: The invention discloses a newly discovered Flt3 phosphorylation site, tyrosine 969 (Tyr969) in the intracellular domain, and provides reagents, including polyclonal and monoclonal antibodies, that selectively bind to Flt3 when phosphorylated at this site. Also provided are assays utilizing this reagent, including methods for determining the phosphorylation of Flt3 in a biological sample, selecting a patient suitable for Flt3 inhibitor therapy, profiling Flt3 activation in a test tissue, and identifying a compound that modulates phosphorylation of Flt3 in a test tissue, by using a detectable reagent, such as the disclosed antibody, that binds to Flt3 only when phosphorylated at Tyr969. The sample or test tissue may be taken from a subject suspected of having cancer, such as acute myelogenous leukemia (AML).Type: ApplicationFiled: March 2, 2007Publication date: April 15, 2010Inventors: Valerie GOSS, Roberto Polakiewicz, Kimberly Lee, Ting-Lei Gu, Albrecht Moritz, Jiong Wu